{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".2","upperLimit":"31.9","value":"6.7"},{"groupId":"OG001","lowerLimit":"29.9","upperLimit":"70.1","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Nadir growth hormone \\<1 ng/mL during a standard 2 hour oral glucose tolerance test using 75 g glucose and normal IGF-I according to age and gender-matched standards.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery\n\nOctreotide LAR","id":"OG000","title":"Medical Treatment by Octreotide LAR"},{"description":"Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured\n\nOctreotide LAR\n\ntranssphenoidal surgery","id":"OG001","title":"Surgical Debulking Followed by Octreotide LAR"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 months","title":"Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}